Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nyse  >  AbbVie    ABBV

ABBVIE

(ABBV)
  Report  
Real-time Quote. Real-time Cboe BZX - 07/23 04:52:53 pm
67.55 USD   -0.66%
07/22ALLERGAN : Form 8.3 -
DJ
07/19ABBVIE : Form 8.3 -
AQ
07/18ABBVIE : Form 8.3 -
DJ
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsOfficial PublicationsSector newsAnalyst Recommendations

AbbVie : Nears Deal to Buy Allergan for More Than $60 Billion

share with twitter share with LinkedIn share with facebook
share via e-mail
0
06/25/2019 | 06:42am EDT

By Cara Lombardo, Jonathan D. Rockoff and Dana Cimilluca

AbbVie Inc. is nearing a deal to buy Allergan PLC for more than $60 billion, according to people familiar with the matter, as the two big drugmakers bet a combination will deliver new sources of growth they have struggled to find on their own.

The takeover, worth $188 a share in cash and stock, is expected to be announced later Tuesday, the people said. The price, mainly to be paid in cash, represents a 45% premium over Allergan's closing share price Monday of $129.57. If not for a surge in the shares in recent days on expectations for a breakup of the company, the premium would be even bigger.

Buying Dublin-based Allergan would deliver a dominant position in the $8 billion-plus market for Botox and other beauty drugs, as well as a number of popular eye treatments, as AbbVie braces for the end of patent protection for the world's top-selling drug, Humira.

The companies' portfolios have some overlap in treatments for brain, women's-health, stomach and other disorders, though the combination would take AbbVie into the new realm of frown-line smoothing, eyelash lengthening and double-chin removal.

Allergan's nearly $16 billion in yearly revenue would also give AbbVie another source of cash to hunt for a new generation of products.

Stocks mentioned in the article
ChangeLast1st jan.
ABBVIE -0.40% 67.73 Delayed Quote.-26.24%
ALLERGAN PLC -0.46% 161.89 Delayed Quote.21.67%
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on ABBVIE
07/22ALLERGAN : Form 8.3 -
DJ
07/19ABBVIE : Form 8.3 -
AQ
07/18ABBVIE : Form 8.3 -
DJ
07/18Novartis raises full-year targets, aims to settle U.S. lawsuit
RE
07/18Novartis raises full-year targets, aims to settle U.S. lawsuit
RE
07/16ABBVIE INC. : Entry into a Material Definitive Agreement, Creation of a Direct F..
AQ
07/15Gilead invests $5 billion to deepen ties with biotech Galapagos
RE
07/15Gilead invests $5 billion to deepen ties with biotech Galapagos
RE
07/15ALLERGAN : Form 8.3 -
DJ
07/15ABBVIE : Enhances Early Stage Oncology Pipeline with Acquisition of Mavupharma
PR
More news
Financials (USD)
Sales 2019 32 953 M
EBIT 2019 15 564 M
Net income 2019 10 755 M
Debt 2019 31 154 M
Yield 2019 6,26%
P/E ratio 2019 9,25x
P/E ratio 2020 8,25x
EV / Sales2019 3,98x
EV / Sales2020 3,67x
Capitalization 100 B
Chart ABBVIE
Duration : Period :
AbbVie Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ABBVIE
Short TermMid-TermLong Term
TrendsNeutralBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 12
Average target price 87,00  $
Last Close Price 67,73  $
Spread / Highest target 69,8%
Spread / Average Target 28,5%
Spread / Lowest Target 7,78%
EPS Revisions
Managers
NameTitle
Richard A. Gonzalez Chairman & Chief Executive Officer
Michael E. Severino Vice Chairman & President
Azita Saleki-Gerhardt Senior Vice President-Operations
Robert A. Michael Chief Financial Officer & Senior Vice President
Carlos Alban Vice Chairman & Chief Commercial Officer
Sector and Competitors
1st jan.Capitalization (M$)
ABBVIE-26.24%100 529
JOHNSON & JOHNSON0.98%341 546
PFIZER-2.02%237 728
ROCHE HOLDING LTD.8.73%230 511
ROCHE HOLDING10.69%230 511
NOVARTIS24.78%216 127